Skip to main content
SpringerLink
Log in
Book cover

Tumor Marker Protocols pp 61–91Cite as

Clinical Application of Tissue and Serum Markers in Breast Cancer

  • Protocol

Part of the book series: Methods in Molecular Medicine™ ((MIMM,volume 14))

Abstract

How different the practice of oncology would become if physicians could predict which of their patients will develop cancer, and, if the disease does occur, then determine who might remain disease-free. Programs stressing prevention, early detection, and prompt treatment could be armed at the approprrate populatron, relieving anxiety in those destined to remam disease-free, and targeting treatment to improve what might have been the predicted outcome. Not only would our patients benefit, but expensive resources could be allocated more effectively.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Hansen M F, Koufos A, Gallie B. L, Phillips R. A, Fodstad O, Brogger A., Gedde-Dahl T, and Cavenee W. K (1985) Osteosarcoma and retinoblastoma. a shared chromosomal mechanism revealing recessive predisposition. Proc Nati Acad Sci USA 82, 6216–6220

    Article  CAS  Google Scholar 

  2. Cavenee W K., Hansen M F., Nordenskjold M., Kock E, Maumenee I., Squire J. A, Phillips R A, and Galhe B. L (1985) Genetic origin of mutations predisposing to retinoblastoma. Science 228, 501–503

    Article  PubMed  CAS  Google Scholar 

  3. Cavenee W K, Dryja T P., Phillps R. A, Benedict W. F, Godbout R, Gallie B. L, Murphree A L, Strong L C., and White R L (1983) Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305, 779–784

    Article  PubMed  CAS  Google Scholar 

  4. Schwartz G F., Schwarting R, Cornfield D B, Shen R, and McDade T. (1996) Subchmcal duct carcmoma of the breast (DCIS) Treatment by local excision and surverllance alone Proc Am Soc Clin Oncol 199, 15

    Google Scholar 

  5. Charpin C. L, Andrac B, Devictor M. C., Habib H., Vacheret L., Xerri M, Lavaut N, and Toga M (1989) Type IV collagen immunostaning and computerized image analysts (SAMBA) in breast and endometrial disorders Histopathology 14, 47–60

    Article  PubMed  CAS  Google Scholar 

  6. Lanzafame S and Puzzo L. (1988) Morpho-functional changes in the basement membrane in benign disease and in premvasive and microinvasive carcinoma of the breast immunohtstochemical study with anti-collagen IV monoclonal antibody [Italran]. Pathologica 80, 309–318

    PubMed  CAS  Google Scholar 

  7. Fisher B., Gunduz N, Costantmo J, Fisher E R., Redmond C., Mamounas E P., and Sidents R. (1991) DNA flow cytometrtc analysis of primary operable breast cancer Relation of ploidy and S-phase fractton to outcome of patients in NSABP B-04. Cancer 68, 1465–1475.

    Article  PubMed  CAS  Google Scholar 

  8. Frierson H F, Jr (1991) Ploidy analysis and S-phase fraction determination by flow cytometry of invaslve adenocarcinomas of the breast Am J Surg Pathol 15, 358–367

    Article  PubMed  Google Scholar 

  9. Joensuu H, Torkkanen S., and Kleml P J. (1990) DNA mdex and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma Cancer 66, 33l–340.

    Article  Google Scholar 

  10. Ngan B. Y, Chen-Levy S, Weiss L. M., Warnke R A, and Cleary M. L. (1988) Expresston in non-Hodgkin’s lymphoma of the bcl-2 protein assoctated with the t(14,18) chromosomal translocation. N Engl J Med. 318, 1638–1644

    Article  PubMed  CAS  Google Scholar 

  11. Negrini M, Silini E, Kozak C, TsuJimoto Y., and Croce C. M (1987) Molecular analysis of mbcl-2 structure and expression of the murine gene homologous to the human gene involved in follicular lymphoma. Cell 49, 455–463

    Article  PubMed  CAS  Google Scholar 

  12. Tsujimoto Y and Croce C M (1986) Analysis of the structure, transcrtpts, and protein products of bcl-2, the gene involved in human folitcular lymphoma Proc Natl Acad Scz USA 83, 5214–5218

    Article  CAS  Google Scholar 

  13. Hayes D F, Zurawski V. R., Jr., and Kufe D W (1986) Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J. Clzn Oncol 4, 1542–1550

    CAS  Google Scholar 

  14. O’Brten D P., Horgran P. G., Gough D. B., Skehill R., Grimes H., and Given H F (1992) CA15-3 a reliable indicator of metastatic bone disease in breast cancer patients Ann Roy Co11 Surg Engl 74, 9

    Google Scholar 

  15. van Dalen A. (1996) New markers for breast carcmoma-associated antigen in comparison with CA 15-3 Antzcancer Res 16, 2339–32343.

    Google Scholar 

  16. Fisher B., Redmond C., Fisher E R, and Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologtc characteristics of differentiation as indicators of prognosis in node negattve breast cancer patients findings from National Surgical AdJuvant Breast and Bowel Project Protocol B-06 J Clin Oncol 6, 1076–1087

    PubMed  CAS  Google Scholar 

  17. Bloom H. J G. and Richardson W. W. (1957) Histological grading and prognosis in node-negative breast cancer. Br J Cancer 11, 359–377

    Article  PubMed  CAS  Google Scholar 

  18. Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Ferno M, Killander D, and Olsson H (1990) Indicators of prognosis in node-negattve breast cancer N Engl J Med 322, 1045–1053

    Article  PubMed  CAS  Google Scholar 

  19. McGuire W L and Clark G M (1992) Prognostic factors and treatment decistons in axtillary-node-negative breast cancer N Engl J Med 326, 1756–1761

    Article  PubMed  CAS  Google Scholar 

  20. Gerdes J, Lemke H., Baisch H., Wacker H H, Schwab U, and Stem H (1984) Cell cycle analysis of a cell prohferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133, 1710–1715

    PubMed  CAS  Google Scholar 

  21. Brown D C and Gatter K C (1990) Monoclonal anttbody Ki-67 its use in histopathology Hzstopathology 17, 489–503

    Article  CAS  Google Scholar 

  22. Schwarting R, Gerdes J, Ntehus J, Jaeschke L, and Stem H (1986) Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67. J lmmunol Methods 90, 65–70

    Article  CAS  Google Scholar 

  23. Cattoretti G., Becker M H., Key G, Duchrow M, Schluter C, Galle J, and Gerdes J. (1992) Monoclonal antibodies against recombinant parts of the Kt-67 antrgen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalm-fixed paraffin secttons. J Pathol 168, 357–363

    Article  PubMed  CAS  Google Scholar 

  24. Schwarti G. F, Finkel G C., Garcia J. C., and Patchefsky A. S. (1992) Subclinical ductal carcmoma tn situ of the breast Treatment by local excision and surveillance alone. Cancer 70, 2468–2474

    Article  Google Scholar 

  25. Mathews M B, Bernstein R. M., Franza B R, Jr., and Garrels J. I. (1984) Identity of the proliferating cell nuclear antigen and cyclin. Nature 309, 374–376.

    Article  PubMed  CAS  Google Scholar 

  26. Hall P A., Levison D. A, Woods A. L., Yu C. C., Kellock D. B., Watkins J A, Barnes D. M, Gillett C E, CampleJohn R., and Dover R (1990) Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections. an index of cell prohferation wtth evidence of deregulated expresslon in some neoplasms J Pathol. 162, 285–294

    Article  PubMed  CAS  Google Scholar 

  27. Leonardi E, Gnlando S, Serio G., Mauri F. A., Perrone G., Scampim S., Dalla Palma P., and Barbareschi M. (1992) PCNA and Ki67 expression in breast carcmoma. correlations with clinical and biological vartables. J. Clzn Pathol 45, 416–419

    Article  CAS  Google Scholar 

  28. Tervahauta A., Eskelmen M., Syrjanen S., Lipponen P., PaJarinen P., and Syqanen K. (1991) Immunohistochemical demonstratton of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic sigmficance. Anticancer Res 11, 1677–1681.

    PubMed  CAS  Google Scholar 

  29. Clark G M and McGune W L. (1991) Follow-up study of HER-Yneu amphfication in primary breast cancer. Cancer Res 51, 944–948

    PubMed  CAS  Google Scholar 

  30. Treurniet H. F., Rookus M. A., Peterse H L., Hart A A., and van Leeuwen F E (1992) Differences in breast cancer risk factors to neu (c-erbB-2) protein overexpression of the breast tumor Cancer Res 52, 2344,2345.

    Google Scholar 

  31. Kaufman P A, Guyre L. D, and Lewis F H. (1996) HER-2/neu targeted immunotherapy a pilot study of multi-dose MCX-210 in patients with breast or ovanan cancers that overexpress HER-2/neu and a report of an increased incidence of HER-2/neu overexpression in metastatic breast cancer. Tumor Targeting 2, 17–27

    CAS  Google Scholar 

  32. Harris C. C and Hollstem M (1992) p53 tumor suppressor gene, in PPO Updates (DeVita V T, Hellman S, and Rosenberg S. A, eds ), Bristol Myers Oncology Division, p 1

    Google Scholar 

  33. Thor A D, Moore D. H, Edgerton S M, Kawasaki E S, Relhsaus E, Lynch H. T, Marcus J. N., Schwartz L., Chen L C, Mayall B H, et al (1992) Accumulation of p53 tumor suppressor gene protein an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84, 845–855

    Article  PubMed  CAS  Google Scholar 

  34. Mousses S, Ozcehk H, Lee P D, Malkm D., Bull S. B., and Andrults I L (1995) Two variants of the CIPl/WAFl gene occur together and are associated with human cancer. Hum Mel Genet 4, 1089–1092.

    Article  CAS  Google Scholar 

  35. Musgrove E. A, Lihschkts R, Cormsh A. L, Lee C. S, Setlur V, Seshadri R., and Sutherland R. L (1995) Expression of the cyclm-dependent kinase inhibitors p16INK4, p15INK4B and p21WAFl/CIPl in human breast cancer Int. J Cancer 63, 584–591

    Article  PubMed  CAS  Google Scholar 

  36. Jeoung D. I, Tang B., and Sonenberg M. (1995) Induction of tumor suppressor p21 protein by kmase mhtbitors in MCF-7 cells Blochem Bzophys Res. Commun 214, 361–366.

    Article  CAS  Google Scholar 

  37. Shetkh M. S, Rochefort H., and Garcia M (1995) Overexpression of p21WAFUCIP1 induces growth arrest, grant cell formation and apoptosts in human breast carcinoma cell lines Oncogene 11, 1899–1905

    Google Scholar 

  38. Stoscheck C. M. and King L E., Jr. (1986) Role of eptdermal growth factor in carcmogenesis Cancer Res 46, 1030–1037

    PubMed  CAS  Google Scholar 

  39. Klijn J G., Berns P M, Schmitz P. I., and Foekens J. A (1992) The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13, 3–17.

    PubMed  CAS  Google Scholar 

  40. Field J. K. and Spandidos D A (1990) The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis. Anticancer Rex 10, 1–22

    CAS  Google Scholar 

  41. Escot C., Theillet C, Lidereau R., Spyratos F, Champeme M H., Gest J, and Callahan R. (1986) Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas Proc Natl Acad,Scl. USA 83, 4834–4838

    Article  CAS  Google Scholar 

  42. Joensuu H., Pylkkanen L, and Totkkanen S. (1994) Bcl-2 protein expression and long-term survival in breast cancer Am J Pathol 145, 1191–1198

    PubMed  CAS  Google Scholar 

  43. Gee J. M., Robertson J. F., Ellis I. O., Willsher P, McClelland R. A., Hoyle H. B, Kyme S R, Finlay P, Blarney R W., and Nicholson R I (1994) Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrme therapy. Int J Cancer 59, 619–628.

    Article  PubMed  CAS  Google Scholar 

  44. Sierra A, Lloveras B., Castellague X, Moreno L, Garcia-Ramnez M, and Fabra A (1995) Bcl expression is associated with lymph node metastasis in human ductal breast carcinoma Int. J Cancer 60, 54–60.

    Article  PubMed  CAS  Google Scholar 

  45. Stlvestrim R, Venerom S, Daidone M. G, Benmi E., Boracchi P, Mezzetti M., Di Fronzo G., Rilke F., and Veronesi U (1994) The Bel-2 protein a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl. Cancer Inst 86, 499–504

    Article  Google Scholar 

  46. Leek R. D., Kaklamanis L, Pezzella F, Gatter K. C, and Harris A. L (1994) bcl-2 in normal human breast and carcmoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer Br J Cancer 69, 135–139

    Article  PubMed  CAS  Google Scholar 

  47. Spyratos F., Maudelonde T, Brouillet J. P, Brunet M, Defrenne A, Andrieu C, Hacene K, Desplaces A, Rouesse J., and Rochefort H. (1989) Cathepsin D. an independent prognostic factor for metastasis of breast cancer HER-2/neu oncogene proteie and prognosis in breast cancer Lancet 7, 1115–1118.

    Article  Google Scholar 

  48. Tandon A K., Clark G. M., Chirgwin M, and McGuue W. L (1990) Cathepsin D and prognosis in breast cancer N Engl J. Med. 322, 297–302.

    Article  PubMed  CAS  Google Scholar 

  49. Aranda F. I and Laforga J. B (1996) Microvessel quantitation in breast ductal invasive carcinoma Correlation with proliferative activity, hormonal receptors and lymph node metastases. Pathol Res Pratt 192, 124–129.

    Article  CAS  Google Scholar 

  50. Kohlberger P D., Obermair A., Sliutz G, Heinzl H., Koelbl H, Breitenecker G, Gitsch G., and Kainz C (1996) Quantitative unmunohtstochemlstry of factor VIII-related antigen in breast carcmoma a comparison of computer-assisted image analysis with established counting methods Am J Clin Pathol 105, 705–710.

    PubMed  CAS  Google Scholar 

  51. Axelsson K., LJung B. M., Moore D. H., 2nd, Thor A D., Chew K L, Edgerton S. M, Smith H. S, and Mayall B. H (1995) Tumor anglogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl. Cancer Inst 87, 997–1008

    Article  PubMed  CAS  Google Scholar 

  52. Fox S. B, Turner G D, Leek R. D., Whitehouse R. M., Gatter K. C, and Harris A. L. (1995) The prognostic value of quantitative anglogenesis in breast cancer and role of adhesion molecule expression in tumor endothehum. Breast Cancer Res Treat 36, 219–226.

    Article  PubMed  CAS  Google Scholar 

  53. Bevtlacqua P., Barbareschi M, Verderio P., Boracchi P., Caffo O., Dalla P., Palma S, Meh N., Weidner N., and Gasparini G (1995) Prognostic value of intratumoral microvessel density, a measure of tumor anglogenesis, in nodenegative breast carcmoma—results of a multiparametric study Breast Cancer Res Treat. 36, 205–217

    Article  Google Scholar 

  54. TOI M, Inada K, Suzuki H., and Tominaga T. (1995) Tumor angtogenesis in breast cancer. Its Importance as a prognostic indicator and the association with vascular endothehal growth factor expression Breast Cancer Res. Treat 36, 193–204

    Article  PubMed  CAS  Google Scholar 

  55. Gasparun G. and Harris A L (1995) Clinical importance of the determmatton of tumor anglogenesis in breast carcmoma. much more than a new prognostic tool. J. Clan Oncol 13, 765–782.

    Google Scholar 

  56. Vartaman R K and Weidner N (1994) Correlation of intratumoral endothelial cell prohferatton with microvessel density (tumor angiogenests) and tumor cell proltferatton in breast carcinoma. Am. J. Pathol 144, 1188–1194

    Google Scholar 

  57. Sawan A, Lascu I, Veron M., Anderson J., Wright C, Horne C H., and Angus B. (1994) NDP-K/nm23 expresston in human breast cancer in relation to relapse, survtval, and other prognosttc factors an immunohtstochemical study J Pathol 172, 27–34

    Article  PubMed  CAS  Google Scholar 

  58. Tokunaga Y, Urano T, Furukawa K, Kondo H., Kanematsu T., and Shtku H. (1993) Reduced expression of nm23-Hl, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. Int J Cancer 55, 66–71

    Article  PubMed  CAS  Google Scholar 

  59. Steeg P S, de la Rosa A, Flatow U., MacDonald N. J, Benedict M., and Leone A (1993) Nm23 and breast cancer metastasis. Breast Cancer Res Treat 25, 175–187

    Article  PubMed  CAS  Google Scholar 

  60. Kobayasht S., Iwase H., Itoh Y., Fukuoka H., Yamashita H., Kuzushtma T., Iwata H, Masaoka A, and Kimura N. (1992) Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancers. Jpn J Cancer Res 83, 859–865

    Article  Google Scholar 

  61. Bevtlacqua G, Sobel M. E., Liotta L. A., and Steeg P S (1989) Associatton of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicattons of high metastatic potemal. Cancer Res. 49, 5185–5190.

    Google Scholar 

  62. Nakamura G, Shikata N., Shojt T., Hatano T., Htoki K., and Tsubura A (1995) Immunohistochemical study of mammary and extramammary Paget’s disease. Anticancer Res 15, 467–470.

    PubMed  CAS  Google Scholar 

  63. Sampson J F., O’Malley F., DuPont W. D., and Page D. L. (1994) Heterogeneous expression of nm23 gene product in noninvasive breast carcinoma. Cancer 73, 2352–2358

    Article  Google Scholar 

  64. Goodall R. J., Dawkins H. J., Robbins P. D, Hahnel E, Sarna M, Hahnel R, Papadimitnou J. M, Harvey J M., and Sterrett G F (1994) Evaluation of the expression levels of nm23-Hl mRNA in primary breast cancer, benign breast disease, axlllary lymph nodes and normal breast tissue Pathology 26, 423–428

    Article  PubMed  CAS  Google Scholar 

  65. Cox L A, Chen G, and Lee E Y (1994) Tumor suppressor genes and then roles in breast cancer Breast Cancer Res Treat 32, 19–38

    Article  PubMed  CAS  Google Scholar 

  66. Howlett A R., Petersen 0. W, Steeg P. S, and Bissell M. J. (1994) A novel function for the nm23-Hl gene overexpression in human breast carcinoma cells leads to the formatlon of basement membrane and growth arrest. J Natl Cancer Znst 86, 1838–1844

    Article  CAS  Google Scholar 

  67. Hahnel E., Dawkms H, Robbms P., and Hahnel R (1994) Expression of stromelysm-3 and nm23 in breast carcmoma and related tissues. Znt J Cancer 58, 157–160

    Article  CAS  Google Scholar 

  68. Yamashlta H, Kobayashi S, Iwase H., Itoh Y., Kuzushlma T., Iwata H., Itoh K, Nalto A, Yamashita T, and Masaoka A. (1993) Analysis of oncogenes and tumor suppressor genes in human breast cancer Jpn J Cancer Res 84, 871–878.

    Article  Google Scholar 

  69. Leone A, Flatow U., VanHoutte K., and Steeg P. S (1993) Transfectlon of human nm23-Hl into the human MDA-MB-435 breast carcinoma cell lme. effects on tumor metastatlc potential, colomzation and enzymatic activity. Oncogene 8, 2325–2333.

    PubMed  CAS  Google Scholar 

  70. Royds J A., Stephenson T. J., Rees R. C., Shorthouse A. J, and Sllcocks P. B. (1993) Nm23 protein expression in ductal in situ and invasive human breast carcinoma J Nat1 Cancer Inst 85, 727–731

    Article  CAS  Google Scholar 

  71. Sastre-Garau X, Ovtracht L, Lascu I., Lacombe M. L., Veron M., Bourdache K, and Thlery J P (1992) Ultrastructural lmmunocytochemlcal localization of diphosphate kmase/Nm23 in human cancer cells. Bull Cancer (Paris) 79, 465–470

    CAS  Google Scholar 

  72. Sastre-Garau X., Lacombe M. L, Jouve M., Veron M., and Magdelenat H. (1992) Nucleoslde diphosphate kmase/NM23 expression in breast cancer lack of correlation with lymph-node metastasis Int J Cancer 50, 533–538

    Article  PubMed  CAS  Google Scholar 

  73. Okubo T., Inokuma S, Takeda S., Itoyama S, Kmoshlta K., and Sugawara I. (1995) Expression of nm23-Hl gene product in thyroid, ovary, and breast cancers Cell Biophys 26, 205–213

    PubMed  CAS  Google Scholar 

  74. Beatson G T. (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with lllustrative cases. Lancet 2, 104.

    Article  Google Scholar 

  75. Toft D and Gorskl J. (1966) A receptor molecule for estrogens: lsolatlon from the rat uterus and preliminary characterization. Proc. Natl. Acad Scl USA 55, 1574–1581

    Article  CAS  Google Scholar 

  76. Knight W. A., Livingston R B., Gregory E J., and McGuire W. L. (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer Cancer Res 37, 4669–4671

    PubMed  CAS  Google Scholar 

  77. Sunderland M. C. and McGuire W. L. (1990) Prognostic indicators in invasive breast cancer. Surg Clin North Am 70, 989–1004

    PubMed  CAS  Google Scholar 

  78. Carter S L., Negrim M., Baffa R., Gillum D. R., Rosenberg A. L, Schwartz G F, and Croce C M (1994) Loss of heterozygoslty at 1lq22-q23 in breast cancer Cancer Res 54, 6270–6274.

    PubMed  CAS  Google Scholar 

  79. Patel U, Grundfest-Bromatowski S., Gupta M., and BanerJee S (1994) Microsatellite instabilities at five chromosomes in primary breast tumors Oncogene 9, 3695-3100

    Google Scholar 

  80. Gudmundsson J, Barkardottir R B., Eiriksdotttr G, Baldursson T, Arason A., Egilsson V, and Ingvarsson S (1995) Loss of heterozygosity at chromosome 11 in breast cancer associatton of prognostic factors with genetic alterations. Br J Cancer 72, 696–701

    Article  PubMed  CAS  Google Scholar 

  81. Kashiwaba M, Tamura G, and Ishida M. (1995) Frequent loss of heterozygosity at the deleted in colorectal carcmoma gene locus and its assoctatton with histologic phenotypes in breast carcinoma. Vtrchows Arch 426, 441–446.

    CAS  Google Scholar 

  82. Radford D. M, Fair K. L, Phillips N J, Ritter J H., Steinbrueck T., Holt M S, and Doms-Keller H (1995) Allelotyping of ductal carcinoma in situ of the breast deletion of loci on 8p, 13q, 16q, 17p and 17q Cancer Res 55, 3399–3405.

    PubMed  CAS  Google Scholar 

  83. Contegiacomo A, Pizzl C, De Marchts L, Alimandi M, Delrio P, Dt Palm E, Petrella G., Ottim L, French D, Frati L., et al. (1995) High cell kinetics is associated with amplification of the mt-2, bcl-1, myc and erbB-2 proto-oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancers. Znt J Cancer 61, 1–6

    Article  CAS  Google Scholar 

  84. Iwase H, Greenman J M, Barnes D M., Bobrow L., Hodgson S, and Mathew C. G (1995) Loss of heterozygosity of the oestrogen receptor gene in breast cancer Br J Cancer 7, 448–450

    Article  Google Scholar 

  85. Zhuang Z., Mermo M. J., Chuaqui R, Liotta L. A, and Emmett-Buck M. R. (1995) Identical allelic loss on chromosome 1lq13 in microdissected in situ and invasive human breast cancer. Cancer Res. 55, 467–471.

    PubMed  CAS  Google Scholar 

  86. Chen L C, Matsumura K, Deng G, Kurisu W., LJung B M, Lerman M. I., Waldman F M, and Smtth H. S. (1994) Deletion of two separate regions on chromosome 3p in breast cancers. Cancer Res 54, 3021–3024.

    PubMed  CAS  Google Scholar 

  87. Hampton G. M., Mannermaa A., Winquist R., Alavaikko M., Blanco G., Taskmen P. J., Kivmiemi H, Newsham H., Cavenee W K, and Evans G A (1994) Loss of heterozygostty in sporadtc human breast carcinoma: a common region between 1 lq22 and 1 lq23. 3. Cancer Res. 54, 4586–4589

    PubMed  CAS  Google Scholar 

  88. Cornells R. S., van Vliet M., Vos C. B., Cleton-Jansen A. M., van de ViJver M J., Peterse J L, Khan P. M, Borresen A. L, Cornelisse C. J., and Devtlee P. (1994) Evidence for a gene on 17p 13 3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res 54, 4200–4206.

    Google Scholar 

  89. Kirchweger R., Zeillinger R., Schneeberger C., Speiser P., Louason G., and Thetllet C. (1994) Patterns of allele losses suggest the exrstence of five distinct regions of LOH on chromosome 17 in breast cancer. Int J, Cancer 56, 193–199.

    Article  CAS  Google Scholar 

  90. Casey G., Plummer S., Hoeltge G., Scanlon D., Fasching C., and Stanbridge E. J. (1993) Functtonal evtdence for a breast cancer growth suppressor gene on chromosome 17 Hum Mel Genet 2, 1921–1927

    Article  CAS  Google Scholar 

  91. Eiriksdottrr G., Sigurdsson A., Jonasson J G., Agnarsson B A, Sigurdsson H., Gudmundsson J, Bergthorsson J. T., Barkardottir R B, Egilsson V., and Ingvarsson S (1995) Loss of heterozygosity on chromosome 9 in human breast cancer. association with chmcal variables and genetic changes at other chromosome regions. Int J. Cancer 64, 378–382

    Article  Google Scholar 

  92. Sheng Z M., Marchetti A., Buttitta F., Champeme M. H., Campam D., Bistocchi M, Lidereau R, and Callahan R. (1996) Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcmomas. Br. J Cancer 73, 144–147

    Article  PubMed  CAS  Google Scholar 

  93. Nagai M A., Medeuos A C, Brentani M M, Brentam R. R., Marques L. A., Mazoyer S., and Mulligan L. M (1995) Five distinct deleted regions on chromosome 17 defining different subsets of human primary breast tumors. Oncology 52, 448–453

    Article  PubMed  CAS  Google Scholar 

  94. Cleton-Jansen A M., Collms N., Lakham S R., Weissenbach J., Devtlee P, Cornehsse C. J, and Stratton M. R. (1995) Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13 Br J. Cancer 72, 1241–1244

    Article  PubMed  CAS  Google Scholar 

  95. Yaremko M L., Recant W. M., and Westbrook C A. (1995) Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. Genes Chromosomes Cancer 13, 186–191.

    Article  PubMed  CAS  Google Scholar 

  96. Koreth J., Bethwaite P. B., and McGee J O (1995) Mutation at chromosome 11q23 in human non-familial breast cancer a microdissection microsatellite analysis. J. Pathol. 176, 11–18.

    Article  PubMed  CAS  Google Scholar 

  97. Wmqvist R., Hampton G. M, Mannermaa A, Blanco G., Alavaikko M., Kivimemi H., Taskinen P. J, Evans G. A., Wright F A., Newsham I, et al. (1995) Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 55, 2660–2664.

    Google Scholar 

  98. Kerangueven F., Essioux L, Dib A., Noguchi T, Allione F, Geneix J., Longy M, Lidereau R., Eisinger F., Pebusque M J., et al. (1995) Loss of heterozygosity and linkage analysis in breast carcmoma. indication for a putative third susceptibihty gene on the short arm of chromosome 8. Oncogene 10, 1023–1026

    PubMed  CAS  Google Scholar 

  99. Nagai M. A, Yamamoto L, Salaorni S., Pacheco M. M., Brentam M M, Barbosa E M, Brentani R. R., Mazoyer S., Smith S A., Ponder B. A., et al. (1994) Detailed deletion mapping of chromosome segment 17q 12-21 in sporadic breast tumours. Genes Chromosomes Cancer 11, 58–62

    Article  PubMed  CAS  Google Scholar 

  100. Hall J M, Lee M. K., Newman B., Morrow J. E., Anderson L. A., Huey B., and King M. C (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250, 1684–1689.

    Article  PubMed  CAS  Google Scholar 

  101. Mike Y., Swensen J., Shattuck-Eidens D, Futreal P A, Harshman K, Tavtigian S, Lm Q, Cochran C, Bennett L. M., Ding W., et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCAI Science 266, 66–71.

    Article  Google Scholar 

  102. Wooster R., Neuhausen S. L, Mangion J., Quirk Y., Ford D., Collms N., Nguyen K, Seal S., Tran T, and Averill D. (1994) Localization of a breast cancer susceptlblllty gene, BRCA2, to chromosome 13q12-13. Science 265, 2088–2090

    Article  PubMed  CAS  Google Scholar 

  103. FltzGerald M G, MacDonald D J., Kramer M, Hoover I, O′Nell E, Unsal H., Silva-Arrleto S., Finkelstein D. M., Beer-Romero P., Englert C., Sgrol D. C., Smith B. L., Younger J. W., Garber J E., Duda R. B., Mayzel K A, Isselbacher K J., Friend S H, and Haber D. A (1996) Germ-line BRCAl mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334, 143–149

    Article  Google Scholar 

  104. Struewing J P, Abellovich D., Peretz T., Avishal N, Kaback M M., Collins F S, and Brody L C (1995) The carrier frequency of the BRCAl 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Natl Genet 11, 198–200.

    Article  CAS  Google Scholar 

  105. Neuhausen S, Gllewski T, Norton T., Tran L, McGulre P., Swensen J, Hampel H., Borgen P., Brown K, Skolnick M, Shattuck-Eldens D., Jhanwar S., Goldgar D., and Offit K (1996) Recurrent BRCA2 6174delT mutattons in Ashkenazl Jewish women affected by breast cancer. Nat1 Genet 13, 126–128

    Article  CAS  Google Scholar 

  106. Natlonal Cancer Institute (1988) Clznical Alert. NCT, Bethesda, MD.

    Google Scholar 

  107. Glwk J A (1990) Adjuvant therapy for node-negative breast cancer. a proactive view, in Important Advances in Oncology (DeVlta V T., Hellman S., and Rosenberg S A, eds), J B Lippmcott Co., Phlladelphla, p. 183

    Google Scholar 

  108. Natlonal Cancer Institute (1990) Treatment of early stage breast cancer NIH Consens Dev Conf Consens Statement 8(6)

    Google Scholar 

  109. Glick J A. (1990) in National Cancer Institute: Treatment of early stage breast cancer NIH Consens Dev Conf Consens. Statement 8, Table 1la-l, p. 186

    Google Scholar 

  110. McGulre W L (I988) Estrogen receptor versus nuclear grade as prognostic factors in axlllary node negative breast cancer. J Clin Oncol 6, 1071,1072

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Jefferson Medical College, Philadelphia, PA

    Gordon F. Schwartz

  2. Department of Pathology and Cellular Biology, efferson Medical College, Philadelphia, PA

    Roland Schwarting

Authors
  1. Gordon F. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roland Schwarting
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. AMC Cancer Research Center, Denver, CO

    Margaret Hanausek  & Zbigniew Walaszek  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Humana Press Inc, Totowa, NJ,

About this protocol

Cite this protocol

Schwartz, G.F., Schwarting, R. (1998). Clinical Application of Tissue and Serum Markers in Breast Cancer. In: Hanausek, M., Walaszek, Z. (eds) Tumor Marker Protocols. Methods in Molecular Medicine™, vol 14. Springer, Totowa, NJ. https://doi.org/10.1385/0-89603-380-5:61

Download citation

  • DOI: https://doi.org/10.1385/0-89603-380-5:61

  • Publisher Name: Springer, Totowa, NJ

  • Print ISBN: 978-0-89603-380-1

  • Online ISBN: 978-1-59259-598-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation